Today we're announcing NFX Bio, a new fund initiative led by some of biotech's most successful Founder/CEOs. Our mission is to back seed-stage companies building bio-platforms that solve the biggest challenges facing humanity.

NFX Bio is led by Omri Amirav Drory, Ph.D., Founder/CEO of Genome Compiler (acquired by Twist Bioscience). Joining him on the Investment Committee is Emily LeProust, Ph.D., Co-Founder & CEO of Twist Bioscience (TWST - NASDAQ), as well as NFX GP's James Currier and Gigi Levy-Weiss.

By combining software/data tech with biology, and by architecting businesses with a platform approach, a whole new future of possibilities is unlocked.

Information technology has dominated human progress for forty years. And the next phase is going to be led by Scientist-Founders who build info-tech powered bio companies. The rise of the Scientist-Founder is now.

In this closed-door conversation, Omri, Emily, and James break down what they’re looking for, and what Scientists need to master in order to be CEOs.

Read the full NFX Essay here - https://www.nfx.com/post/launching-nfx-bio/